Large-Scale GWAS Identifies Genetic Predictors of GLP-1 Weight Loss Efficacy and Side Effects

Bottom line: Genetic variation meaningfully predicts who will lose the most weight — and who will experience the worst side effects — on GLP-1 receptor agonists, bringing precision obesity medicine a step closer to reality.

GLP-1 receptor agonists such as semaglutide and tirzepatide have transformed obesity treatment, but individual responses vary enormously. Some patients lose 20% or more of their body weight; others lose little. Until now, clinicians had no reliable way to predict who would benefit most.

A large-scale genome-wide association study (GWAS) published in Nature on April 8, 2026, by the 23andMe Research Institute changes that picture.¹ The study analyzed genetic data from a large cohort of GLP-1 receptor agonist users to identify variants associated with weight loss efficacy and common side effects such as nausea and gastrointestinal symptoms.

Key Findings

The researchers identified multiple genetic loci significantly associated with differential weight loss response to GLP-1 receptor agonists. Importantly, separate genetic signals were found for efficacy (weight loss magnitude) and tolerability (gastrointestinal side effects), suggesting these are biologically distinct pathways.

The identified variants implicate genes involved in central appetite regulation, gut motility, and incretin signaling — pathways that make biological sense given GLP-1's mechanism of action. The study is the largest pharmacogenomic analysis of GLP-1 drugs to date, leveraging 23andMe's unique crowdsourced research model.

Clinical Significance

The findings have immediate translational potential. If validated prospectively, genetic profiling could help clinicians:

• Select the right drug: patients with variants predicting poor GLP-1 response might benefit from alternative or combination approaches such as retatrutide or CagriSema
• Anticipate side effects: patients carrying risk variants for GI intolerance could receive slower titration schedules or prophylactic antiemetics
• Set realistic expectations: personalized weight loss projections could improve adherence and reduce treatment abandonment

23andMe has already translated these findings into a consumer-facing GLP-1 report available through its Total Health platform, though clinical-grade pharmacogenomic testing will require further validation.

Clinical Implication

Prescribers managing patients on GLP-1 receptor agonists should be aware that genetic variation contributes meaningfully to response variability. While routine pharmacogenomic testing is not yet standard of care, this study moves the field closer to a future where a simple genetic test could guide drug selection and dosing in obesity medicine.

---

¹ 23andMe Research Institute. Genetic predictors of GLP1 receptor agonist weight loss and side effects. Nature (2026). DOI: 10.1038/s41586-026-10330-z